Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Vaxcyte Inc’s stock clocked out at $43.94, up 2.54% from its previous closing price of $42.85. In other words, the price has increased by $2.54 from its previous closing price. On the day, 1.93 million shares were traded. PCVX stock price reached its highest trading level at $45.12 during the session, while it also had its lowest trading level at $42.88.
Ratios:
To gain a deeper understanding of PCVX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.11 and its Current Ratio is at 11.11. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on September 12, 2025, initiated with a Neutral rating and assigned the stock a target price of $38.
On December 20, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $135.Goldman initiated its Buy rating on December 20, 2024, with a $135 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 05 ’25 when Eydelman Mikhail sold 5,000 shares for $70.74 per share. The transaction valued at 353,699 led to the insider holds 41,620 shares of the business.
Eydelman Mikhail bought 5,000 shares of PCVX for $344,350 on Mar 05 ’25. On Mar 03 ’25, another insider, Wassil Jim, who serves as the CHIEF OPERATING OFFICER of the company, sold 8,000 shares for $73.27 each. As a result, the insider received 586,165 and left with 154,931 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCVX now has a Market Capitalization of 5704437760 and an Enterprise Value of 4128856320.
Stock Price History:
The Beta on a monthly basis for PCVX is 1.02, which has changed by -0.62935734 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, PCVX has reached a high of $118.62, while it has fallen to a 52-week low of $27.66. The 50-Day Moving Average of the stock is 28.77%, while the 200-Day Moving Average is calculated to be -8.99%.
Shares Statistics:
It appears that PCVX traded 1.65M shares on average per day over the past three months and 2139590 shares per day over the past ten days. A total of 129.82M shares are outstanding, with a floating share count of 125.37M. Insiders hold about 3.43% of the company’s shares, while institutions hold 111.75% stake in the company. Shares short for PCVX as of 1759190400 were 11081540 with a Short Ratio of 6.71, compared to 1756425600 on 11505613. Therefore, it implies a Short% of Shares Outstanding of 11081540 and a Short% of Float of 9.56.
Earnings Estimates
The stock of Vaxcyte Inc (PCVX) is currently being evaluated by 6.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$1.31, with high estimates of -$1.05 and low estimates of -$1.71.
Analysts are recommending an EPS of between -$3.85 and -$5.96 for the fiscal current year, implying an average EPS of -$4.77. EPS for the following year is -$5.81, with 6.0 analysts recommending between -$4.16 and -$7.28.
